Walgreen
explores sale of $1.5 billion infusion business: sources
Send a link to a friend
[September 24, 2014]
By Soyoung Kim and Greg Roumeliotis
NEW YORK (Reuters) - U.S.
drugstore chain operator Walgreen Co is exploring the
sale of a majority stake in its infusion services
business, in a deal that could value that division at
around $1.5 billion, according to four people familiar
with the matter. |
The Deerfield, Illinois-based company has hired Bank of America Corp
<BAC.N> to run a sale process for Walgreens Infusion Services, which
has already attracted interest from private equity firms, the people
said this week.
On offer is a controlling stake of just over 50 percent in Walgreens
Infusion Services, which has annual earnings before interest, tax,
depreciation and amortization of around $105 million, one of the
people added.
The sources asked not to be identified because the talks are
confidential. Walgreen declined to comment while a Bank of America
spokesman did not respond to a request for comment.
With a staff of more than 1,600 clinicians, the unit for sale offers
infusion services at home and at care centers across the United
States. Its infusion therapies are used for medical conditions such
as bleeding disorders and serious infections.
Walgreen is currently the largest U.S. provider of home-infusion
services. The company solidified that position in 2010 when it
swapped its long-term care pharmacy business for the home infusion
business of Omnicare Inc.
A deal for Walgreens Infusion Services would come after rival CVS
Health Corp acquired Coram LLC, the specialty infusion services and
enteral nutrition business unit of Apria Healthcare Group Inc, for
about $2.1 billion in January.
[to top of second column] |
Walgreen has a history of working with private equity. In 2012,
Walgreens acquired a 45 percent stake in European health and beauty
group Alliance Boots for $6.7 billion, partnering with buyout firm
KKR & Co LP and Alliance Boots Chairman Stefano Pessina, that were
left owning the remainder.
Last month, Walgreen said it would buy the remaining 55 percent it
does not already own of Alliance Boots for $5.3 billion in cash and
144.3 million shares for a total deal of about $15 billion.
(Reporting by Soyoung Kim and Greg Roumeliotis in New York; Editing
by Lisa Shumaker)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright
2014 Reuters. All rights reserved. This material may not be
published, broadcast, rewritten or redistributed.
|